CD274 and cancer: The reasons for this discrepancy might be due to different drugs, different antibody clones (validated for specific platforms, e.g. automated Ventana IHC systems or DAKO IHC autostainer), different thresholds, as well as complex pathophysiological mechanisms behind PD-L1 deregulation due to the interactions between cancer and immune cells [10, 15].